Navigation Links
Amylin Pharmaceuticals Reports First Quarter Financial Results
Date:4/16/2009

for the same period in 2008. Net product sales for the quarter ended March 31, 2009 include a reserve of $5.8 million for amounts payable to the U.S. Department of Defense under the Tricare Retail Pharmacy program retroactive to January 28, 2008 pursuant to the issuance of a final rule implementing this program in the quarter ended March 31, 2009.

Revenues under collaborative agreements were $14.3 million for the quarter ended March 31, 2009, compared to $18.5 million for the same period in 2008. The decrease reflects lower cost-sharing payments from Eli Lilly and Company for BYETTA and exenatide once weekly development expenses.

Selling, general and administrative expenses decreased to $87.6 million for the quarter ended March 31, 2009 from $98.2 million for the same period in 2008. The decrease primarily reflects lower promotional spending for BYETTA and SYMLIN and the Company's reduced cost structure following its restructuring.

Research and development expenses decreased to $60.0 million for the quarter ended March 31, 2009 from $77.2 million for the same period in 2008. The decrease primarily reflects lower development expenses for exenatide once weekly and BYETTA, and the Company's reduced cost structure following its restructuring. Research and development expenses for the quarter ended March 31, 2008 also included an $8 million license payment for drug delivery technology. Non-GAAP research and development expenses net of Lilly cost-sharing payments decreased to $46.7 million for the quarter ended March 31, 2009, compared to $59.8 million for the same period in 2008.

Collaborative profit sharing, which represents Lilly's share of the gross margin for BYETTA, was $73.0 million for the quarter ended March 31, 2009, compared to $69.9 million for the same period in 2008.

The Company adopted Financial Statement Accounting Standards Board Staff Position (FSP) APB 14-1, "Acco
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Letter From Carl Icahn to Amylin Pharmaceutical, Inc.
2. Amylin Pharmaceuticals to Webcast First Quarter Results
3. Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders
4. Amylin Pharmaceuticals Comments on Shareholder 13-D Filing
5. Amylin Pharmaceuticals Reports 2008 Financial Results
6. Amylin Pharmaceuticals to Webcast Year-End Results
7. Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
8. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
9. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
10. Lilly and Amylin Set Date and Time for Conference Call
11. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 2014 This is a professional and ... Sterilizers industry with a focus on the Chinese market. ... of the Sterilizers manufacturers and is a valuable source ... in the industry. This report provides a basic overview ... technology. In this part, the report presents the company ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... of the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ... Liebhard LLP reports. According to an Order issued in ... November 20th, the Court will convene an open conference ... Federal Building and United States Courthouse in West Palm ...
(Date:12/25/2014)... the popular online supplier of wedding dresses and special occasion ... black one-shoulder cocktail dresses . In addition, all these elegant ... prices, up to 70% off. , The development ... You know, we have thousands of frequent callers in the ... can visit our website for more details. The current special ...
(Date:12/25/2014)... Angeles, CA (PRWEB) December 25, 2014 The ... Dolcemaschio was created in honor of a true 9/11 ... at two film festivals including the 24 hours of Nuremberg ... Festival in Bangladesh. , Actress, screenwriter and director ... helped produce this film together with her husband, Gregory ...
Breaking Medicine News(10 mins):Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... , , BRONX, N.Y., Aug. 3 ... raising their risk of bone and heart disease, according to a study ... striking findings suggest that vitamin D deficiency could place millions of children ... disease. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090803/DC55348 ...
... But another study finding suggests insulin treatment could boost ... Metformin, one of the most widely used diabetes drugs, ... odds for pancreatic cancer by 60 percent, a new ... Other common treatments, including the use of insulin or ...
... ER treatments since 1990 , SUNDAY, Aug. 2 (HealthDay News) ... climbing for fun and exercise, the number of injuries related ... study on the subject. , More than 40,000 people sought ... fractures, sprains and other ailments related to rock-climbing -- a ...
... ... be joining dental sleep medicine,s top sleep and dental sleep professionals at Somnomed,s first annual ... ... Isn,t Sexy, LLC will be joining dental sleep medicine,s top sleep and dental sleep professionals ...
... cell lung cancer (NSCLC) patients over the age of ... erlotinib, Fox Chase Cancer Center researchers reported today at ... Study of Lung Cancer. "Based on our initial ... efficacious, though we,ll have to wait and see the ...
... , NASHVILLE, Tenn., Aug. 1 HCA Healthcare announces the following Webcast: , , ... Healthcare Webcast , , When: August ... http://www.videonewswire.com/event.asp?id=60459 , , How: ... the web at the address above. , , Contact: ...
Cached Medicine News:Health News:Millions Of U.S. Children Low In Vitamin D 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 3Health News:Rock-Climbing Injury Rate Soaring 2Health News:Laurence I. Barsh, DMD, Founder of Snoring Isn't Sexy, to speak at Somnomed's First Annual Symposium 2Health News:Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients 2
(Date:12/24/2014)... 24, 2014  Actavis plc (NYSE: ... received a complete response letter from the U.S. ... Drug Application (NDA) for the fixed-dose combination (FDC) ... hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... the receipt of a complete response letter, Actavis ...
(Date:12/24/2014)... Dec. 24, 2014  The International Trade Commission (ITC) issued ... against BMC Medical. In a notice issued on December 23, ... ResMed,s patent on its humidifier was invalid. BMC ... win". "We are very excited with the ITC,s decision in ... we have taken since the very beginning on the key ...
(Date:12/24/2014)... -- PuraMed BioScience®, Inc., (OTC Pink: PMBS), a researcher, ... products, announced it received the initial funding to begin ... relief product, for planned distribution to 1,000 medical and ... Washington State , and ... Advanced headache relief gel formulation completed, PuraMed BioScience has ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... it implements the confocal principle, the design ... unmatched. It allows multi fluorescence images to ... Unprecedented flexibility for individual applications. Entirely new ... and efficient structural and functional analysis of ...
... new Eclipse TS100 is an innovative ... high quality tool complements any research ... Image Documentation: Nikon offers the TS100 ... TS100-F trinocular model comes with a ...
... system designed for scientific microscope imaging ... cameras provides high-resolution, full-color images and ... PC via its Firewire (IEEE 1394) ... is accompanied by automatic white balance ...
... camera system designed for scientific microscope ... digital cameras provides high-resolution, full-color images ... a PC via its Firewire (IEEE ... capability is accompanied by automatic white ...
Medicine Products: